IXICO supports the Alzheimer's Disease Neuroimaging Initiative

We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.

IXICO today announced funding support for the Alzheimer's Disease Neuroimaging Initiative (ADNI), and two of their scientists will join the ADNI-Private Partner Scientific Board (PPSB).

Watch our Chief Product Officer, Alison Howie's interview with proactive to learn more about IXICO's role within the ADNI partnership.

ADNI is a longitudinal multicentre study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). Its goals are to detect AD at the earliest stage possible (pre-dementia) and identify ways to track the disease's progression with biomarkers, as well as to support advances in AD intervention, prevention, and treatment through the application of new diagnostic methods in a pre-competitive environment and through data sharing to advance the field in AD.

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We are proud to support the ADNI initiative which has made a major contribution to setting the imaging standards in AD research and provides access to important clinical data sets to the global research community. ADNI's purpose is well-aligned with our own goal to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare which will contribute to the advancement of AD research. We look forward to engaging with all members of the consortium to contribute to the success of this initiative."

The ADNI-PPSB, convened by the Foundation for the National Institutes of Health, facilitates open dialogue around the progress of the ADNI project, as well as new trends with Alzheimer's disease-related research and development. "The FNIH is pleased to welcome IXICO to the ADNI-PPSB," said Joseph Menetski, Ph.D., Associate Vice President, FNIH. "IXICO's expertise in data analytics will be a valuable contribution to the role the ADNI-PPSB plays to help develop biomarkers that advance the field of Alzheimer's disease research."

For information on IXICO's partnerships with consortia and charitable organisations, visit our collaborations page here


Date: 03/02/2020